New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 6, 2013
11:49 EDTAMAGAMAG sees FY13 COGS of between 14% and 18% of net product sales
AMAG sees FY13 cost of goods sold, COGS, of between 14% and 18% of net product sales; Total operating expenses, excluding COGS, of between $78M and $82M, representing an approximate 10% reduction from 2012. The reduced operating expenses in 2013 will be driven by decreased clinical trial costs, offset in part by new investments in a lower-cost production process and pre-launch investments to support a potential expansion to Feraheme’s label. The company expects: Research and development expenses of between $24M and $27M, representing an approximate 27% reduction from 2012; Selling, general and administrative expenses of between $54M and $57M, representing an approximate 2% increase from 2012.
News For AMAG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 26, 2015
17:59 EDTAMAGAdage capital reports 10.7% passive stake in AMAG Pharmaceuticals
Subscribe for More Information
February 25, 2015
18:32 EDTAMAGAMAG Pharmaceuticals 3.98M share Secondary priced at $44.00
Subscribe for More Information
February 24, 2015
18:15 EDTAMAGOn The Fly: After Hours Movers
Subscribe for More Information
16:06 EDTAMAGAMAG Pharmaceuticals files to sell $125M in common stock
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use